In vitro structure-function analysis of the β-strand 326-333 of human p53

Journal of Molecular Biology

Volumn 273, Issue 4, 1997, Pages 873-881

  Chène, Patrick ^b   Mittl, Peer ^a   Grütter, Markus ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE

Author keywords

p53; Protein interface; Protein protein interactions; Tetramerisation; sheet

Indexed keywords

ARGININE; DNA BINDING PROTEIN; GLUTAMIC ACID; GLYCINE; MUTANT PROTEIN; PROTEIN P53; TETRAMER; THREONINE; TYROSINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STEREOCHEMISTRY;

ANIMALIA;

EID: 0031558782     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1997.1360     Document Type: Article

References (38)

1. Abarzua P., LoSardo J. E., Gubler M. L., Neri A. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res. 55:1995;3490-3494.
2. Attardi L. D., Lowe S. W., Brugarolas J., Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 15:1996;3693-3701.
3. Bayle J. H., Elenbaas B., Levine A. J. The carboxy-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc. Natl Acad. Sci. USA. 92:1995;5729-5733.
4. Brachmann R. K., Vidal M., Boeke J. D. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc. Natl Acad. Sci. USA. 1996.
5. Chène P. A fast semi quantitative determination of the DNA binding activity ofin vitro. BioTechniques. in the press:1997.
6. Clore G. M., Omichinski J. G., Sakaguchi K., Zambrano N., Sakamoto H., Appella E., Gronenborn A. M. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science. 265:1994;386-391.
7. Di Leonardo A., Linke S. P., Clarkin K., Wahl G. M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8:1994;2540-2551.
8. El Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1 a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
9. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein by DNA-damaging agents. Oncogene. 8:1993;307-318.
10. Hainaut P., Hall A., Milner J. Analysis of p53 quaternary structure in relation to sequence-specific DNA binding. Oncogene. 9:1994;299-303.
11. Halazonetis T. D., Kandil A. N. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 12:1993;5057-5064.
12. Harvey M., Vogel H., Morris D., Bradley A., Bernstein A., Donehower L. A. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genet. 9:1995;305-311.
13. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 253:1991;49-53.
14. Hollstein M., Shomer B., Greenblatt M., Soussi T., Hovig E., Montesano R., Harris C. C. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucl. Acids Res. 24:1996;141-146.
15. Huang L. C., Clarkin K. C., Wahl G. M. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc. Natl Acad. Sci. USA. 93:1996;4827-4832.
16. Hupp T. R., Lane D. P. Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. Cold Spring Harbor Symp. Quant. Biol. 59:1994;195-206.
17. Hupp T. R., Meek D. W., Midgley C. A., Lane D. P. Regulation of the specific DNA binding function of p53. Cell. 71:1992;875-886.
18. Hupp T. R., Sparks A., Lane D. P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell. 83:1995;237-245.
19. Jayaraman J., Prives C. Activation of p53-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell. 81:1995;1021-1029.
20. Jeffrey P. D., Gorina S., Pavletich N. P. Crystal structure of the p53 tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 267:1995;1498-1502.
21. Johnson C. R., Morin P. E., Arrowsmith C. H., Freire E. Thermodynamic analysis of the structural stability of the tetrameric oligomerization domain of p53 tumor suppressor. Biochemistry. 34:1995;5309-5316.
22. Lane D. P., Midgley C. A., Hupp T. R., Lu X., Vojtesek B., Picksley S. M. On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage. Phil. Trans. Roy. Soc. ser.B. 347:1995;83-87.
23. Lee W., Harvey T. S., Yin Y., Yau P., Litchfield D., Arrowsmith C. H. Solution structure of the tetrameric minimum transforming domain of p53. Struct. Biol. 1994.
24. Lu X., Lane D. P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell. 75:1993;765-778.
25. Milner J., Medcalf E. A. Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 protein into the mutant conformation. Cell. 65:1991;765-774.
26. Milner J., Medcalf E. A., Cook A. C. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol. Cell Biol. 1991.
27. Mittl P., Chène P., Grütter M. Crystallization and structure solution of p53 (residue 326-356) by molecular replacement using a NMR model as template. Acta Crystallog. sect. D. in the press:1997.
28. Nelson W. G., Kastan M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14:1994;1815-1823.
29. Polyak K., Waldman T., He T. C., Kinzler K. W., Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10:1996;1945-1952.
30. Selivanova G., Wiman K. G. p53: a cell cycle regulator activated by DNA damage. Advan. Cancer Res. 66:1995;143-180.
31. Shaulian E., Zauberman A., Milner J., Davies E. A., Oren M. Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. EMBO J. 12:1993;2789-2797.
32. Stenger J. E., Tegtmeyer P., Mayr G. A., Reed M., Wang Y., Wang P., Hough P. V., Mastrangelo I. A. p53 oligomerization and DNA looping are linked with transcriptional activation. EMBO J. 13:1994;6011-6020.
33. Tarunina M., Jenkins J. R. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity. Oncogene. 8:1993;3165-3173.
34. Vasey P. A., Jones N. A., Jenkins S., Dive C., Brown R. Cisplatin, camptothecin and taxol sensitivities of cells with p53-associated multidrug resistance. Mol. Pharmacol. 50:1996;1536-1540.
35. Waterman J. L., Shenk J. L., Halazonetis T. D. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J. 14:1995;512-519.
36. Waterman M. J. F., Waterman J. L. F., Halazonetis T. D. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived mutants. Cancer Research. 56:1996;158-163.
37. Webster N. J. G., Resnik J. L., Reichart D. B., Strauss B., Haas M., Seely B. L. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Res. 56:1996;2781-2788.
38. Zhang W., Guo X. Y., Deisseroth A. B. The requirement of the carboxyl terminus of p53 for DNA binding and transcriptional activation depends on the specific p53 binding DNA element. Oncogene. 9:1994;2513-2521.